Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AcelRx Pharmaceuticals, Inc.    ACRX


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AcelRx Pharmaceuticals : Reports Third Quarter 2020 Financial Results

11/06/2020 | 09:10am EST

REDWOOD CITY - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter 2020 financial results.

'The third quarter represented one of our most active and successful quarters since DSUVIA's approval,' said Vince Angotti, Chief Executive Officer of AcelRx. 'We've made significant progress on our revenue growth strategy, highlighted by our oral and dental surgery collaboration with Zimmer Biomet, the addition of DSUVIA to the Department of Defense Joint Deployment Formulary and our new U.S. Army contract. With the recent publication of data supporting DSUVIA's strong value proposition, we have gained momentum in DSUVIA's use within existing hospital and ambulatory surgery center customers, and the rate of scheduled formulary reviews. Progress within the Department of Defense continues and we expect the initial ordering of DSUVIA for deployed troops in the fourth quarter.'

Third Quarter Highlights

In July, AcelRx entered into a distribution agreement with Zimmer Biomet to market DSUVIA within the dental and oral surgery markets in the United States exclusively through Zimmer Biomet's Dental division, expanding U.S. availability of DSUVIA. It is estimated that the applicable market in dental surgeries is over 7 million annual procedures.

In July, AcelRx completed a $10 million common stock offering priced at the market with two leading life science investors.

In August, AcelRx announced the publication of a study entitled 'Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative Administration of Sublingual Sufentanil in an Ambulatory Surgery Setting,' by Christian Tvetenstrand, MD and Michael Wolff, MD, in the Journal of Clinical Anesthesia and Pain Management. Highlights of the publication included a greater than 50% overall reduction in opioids administered perioperatively and a 34% reduction in PACU time in the DSUVIA-treated patients compared to historical controls.

In August, AcelRx announced an investigator-initiated study with Cleveland Clinic that will assess the effects of DSUVIA on post-operative recovery from orthopedic surgery.

In September, AcelRx announced that the U.S. military's access to DSUVIA had been expanded with the addition of DSUVIA to the Department of Defense Joint Deployment Formulary (JDF).

In September, the U.S. Army awarded AcelRx with an initial contract of up to $3.6 million over four years for the purchase of DSUVIA to support a DoD study to aid the development of clinical practice guidelines.

Financial Information

Cash, cash equivalents and short-term investments balance was $43.0 million as of September 30, 2020.

Net revenues for the third quarter 2020 were $1.4 million, of which approximately $1.3 million relates to product sales (compared to $0.3 million in product sales for the second quarter of 2020).

Combined R&D and SG&A expenses for the third quarter of 2020 totaled $8.6 million, a significant reduction compared to $12.0 million for the third quarter of 2019. Excluding stock-based compensation expense, these amounts were $7.5 million for the third quarter of 2020 compared to $10.7 million for the third quarter of 2019. The decrease in combined R&D and SG&A expenses in the third quarter of 2020 was primarily due to a reduction of $1.8 million in personnel costs and a $1.1 million reduction in DSUVIA-related commercialization expenses.

Net loss for the third quarter of 2020 was $8.9 million, or $0.10 per basic and diluted share, compared to $12.7 million, or $0.16 per basic and diluted share, for the third quarter of 2019.

About DSUVIA (sufentanil sublingual tablet), 30 mcg

DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018, is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with intravenous (IV) administration. DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator (SDA) by healthcare professionals. Sufentanil is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile when delivered sublingually avoids the high peak plasma levels and short duration of action observed with IV administration. The European Commission approved DZUVEO for marketing in Europe in June 2018 and AcelRx is currently in discussions with potential European marketing partners.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.

Non-GAAP Financial Measures

To supplement AcelRx's financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), AcelRx uses certain non-GAAP financial measures in this press release, in particular, excluding stock-based compensation expense from its operating expenses. AcelRx believes that these non-GAAP financial measures provide useful supplementary information to, and facilitate additional analysis by, investors and analysts. In particular, AcelRx believes that these non-GAAP financial measures, when considered together with AcelRx's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare AcelRx's results from period to period and to its forward-looking guidance. In addition, these types of non-GAAP financial measures are regularly used by investors and analysts to model and track AcelRx's financial performance. AcelRx's management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate AcelRx's business and to make operating decisions. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with AcelRx's consolidated financial statements prepared in accordance with GAAP.

Forward-Looking and Cautionary Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the timing and size of military orders, the market for DSUVIA in dental and oral surgeries, the expected commencement of an investigator-initiated study and the scope of the study. These and any other forward-looking statements aremade pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as 'believes,' 'expects,' 'anticipates,' 'may,' 'will,' 'should,' 'seeks,' 'approximately,' 'intends,' 'plans,' 'estimates,' or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied by such statements, including the risk that the military and hospital systems delay, or fail to place, orders, that AcelRx may not experience the expected benefits from the Zimmer Biomet commercial opportunity and the uncertainties inherent in the initiation, execution and completion of investigator-initiated studies. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, those described in AcelRx's annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date such statements were first made. To the degree financial information is included in this press release, it is in summary form only and must be considered in the context of the full details provided in AcelRx's most recent annual, quarterly or current report as filed or furnished with the SEC. AcelRx's SEC reports are available at www.acelrx.com under the 'Investors' tab. Except to the extent required by law, AcelRx undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


Theresa Dolge

Tel: 215-928-2748

Email: theresa.dolge@evokegroup.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ACELRX PHARMACEUTICALS, INC. -3.53% 2.3386 Delayed Quote.94.35%
ZIMMER BIOMET HOLDINGS -0.45% 158.69 Delayed Quote.3.39%
01/21ACELRX PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financi..
01/20ACELRX PHARMACEUTICALS : Prices Public Sale of $27.5 Million of Common Shares
01/20ACELRX PHARMACEUTICALS : Announces Pricing of $27.5 Million Public Offering of C..
01/19ACELRX PHARMACEUTICALS : Announces Share Offering - Stock Slides 7.7% After-Hour..
01/19ACELRX PHARMACEUTICALS : Announces Underwritten Public Offering of Common Stock
01/19ACELRX PHARMACEUTICALS : Announces an Investigator-Initiated Study of DSUVIA® in..
01/14ACELRX PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fina..
01/14ACELRX PHARMACEUTICALS : Announces Year-End 2020 Metrics and Review of 2020 Achi..
2020ACELRX PHARMACEUTICALS : Announces Publication of Clinical Data on Decreased Pos..
2020ACELRX PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (fo..
More news
Financials (USD)
Sales 2020 6,87 M - -
Net income 2020 -41,5 M - -
Net cash 2020 21,0 M - -
P/E ratio 2020 -5,02x
Yield 2020 -
Capitalization 273 M 273 M -
EV / Sales 2020 36,7x
EV / Sales 2021 7,89x
Nbr of Employees 99
Free-Float 97,9%
Duration : Period :
AcelRx Pharmaceuticals, Inc. Technical Analysis Chart | ACRX | US00444T1007 | MarketScreener
Technical analysis trends ACELRX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 5,46 $
Last Close Price 2,41 $
Spread / Highest target 273%
Spread / Average Target 126%
Spread / Lowest Target -65,6%
EPS Revisions
Managers and Directors
Vincent J. Angotti Chief Executive Officer & Director
Adrian Adams Chairman
Raffi Asadorian Chief Financial & Accounting Officer
Pamela Pierce Palmer Director & Chief Medical Officer
Badri N. Dasu Chief Engineering Officer
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.36.65%68 869
BEIGENE, LTD.45.87%34 368